Skip to main content

Enlivex Ltd.

corporate_fare Company Profile

Enlivex Ltd.

ENLV·NASDAQ·Life Sciences·CIK 0001596812

Enlivex Ltd. is a company incorporated under the laws of the State of Israel. The company was originally incorporated as Bioblast Pharma Ltd. on January 22, 2012. On March 26, 2019, Bioblast Pharma Ltd. merged with Enlivex R&D (formerly Enlivex Therapeutics Ltd.), with Enlivex R&D becoming a wholly owned subsidiary of Bioblast. Following the merger, Bioblast Pharma Ltd. changed its name to Enlivex Therapeutics Ltd. In February 2026, the company changed its name to Enlivex Ltd. Its primary operating subsidiary, Enlivex R&D, was initially incorporated as Tolarex Ltd. in September 2005 in Israel. In February 2010, Tolarex Ltd. changed its name to Enlivex Therapeutics Ltd., and after the merger, to Enlivex Therapeutics R&D Ltd. In June 2021, Enlivex Therapeutics RDO Ltd. was established in Israel as a wholly owned subsidiary. The company also has a wholly owned U.S. subsidiary, Enlivex Therapeutics Inc., incorporated in Delaware. Enlivex Ltd.'s principal executive offices are located at 14 Einstein Street, Ness Ziona, Israel 7403618. The company's capital expenditures for the three years ended December 31, 2025, 2024, and 2023 were insignificant.

Enlivex Ltd. (NASDAQ:ENLV) is a publicly traded company in the Life Sciences sector. Wiseek monitors ENLV SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Enlivex Receives FDA IND Clearance for Phase 2b Allocetra Trial in Knee Osteoarthritis
  • Enlivex Updates ATM Program, Confirms $2.5M Sales and Authorizes Up to $250M in Future Dilution
  • Enlivex's RAIN Token Listed on Kraken Exchange, Expanding Digital Asset Access
  • Shareholders Approve Classified Board and Supermajority Voting Amendments
  • Enlivex to Delist from Tel Aviv Stock Exchange, Focus on Nasdaq Trading

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
$1.24B
Diluted EPS
$25.48
Op. Cash Flow
-$10.42M
Free Cash Flow
-$10.48M
Operating Income
-$15.03M
Cash & Equivalents
$1.89M
Debt / Equity
0.00×
Shares Outstanding
237.38M sh
Source: 20-F · filed 2026-03-25 · accession 0001213900-26-033857

Insider Transactions

ENLV files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$2.1
52-week range · as of 2026-07-28 $2.08 – $31.5
Market cap
$35.35M
Volume
236.8K (1.2× avg)
3-mo avg 203.4K
Live data · 2026-07-29 16:12 UTC · Market open

show_chartPrice Chart

Loading chart...

feed ENLV - Filings & News (Page 2)

ENLV
Mar 23, 2026, 8:02 AM EDT
Filing Type: 6-K
Importance Score:
8
Enlivex Receives FDA IND Clearance for Phase 2b Allocetra Trial in Knee Osteoarthritis
Price at Filing: $1.09
Real-time Price: $2.10 info
Change: Reverse Stock Split info
Market Cap: $35.347M info
Sentiment: Positive
View Wiseek Article
ENLV
Mar 20, 2026, 4:05 PM EDT
Filing Type: 424B3
Importance Score:
8
Enlivex Updates ATM Program, Confirms $2.5M Sales and Authorizes Up to $250M in Future Dilution
Price at Filing: $1.02
Real-time Price: $2.10 info
Change: Reverse Stock Split info
Market Cap: $35.347M info
Sentiment: Negative
View Wiseek Article
ENLV
Feb 10, 2026, 8:02 AM EST
Filing Type: 6-K
Importance Score:
7
Enlivex's RAIN Token Listed on Kraken Exchange, Expanding Digital Asset Access
Price at Filing: $1.20
Real-time Price: $2.10 info
Change: Reverse Stock Split info
Market Cap: $35.347M info
Sentiment: Positive
View Wiseek Article
ENLV
Feb 05, 2026, 7:50 AM EST
Filing Type: 6-K
Importance Score:
7
Shareholders Approve Classified Board and Supermajority Voting Amendments
Price at Filing: $1.10
Real-time Price: $2.10 info
Change: Reverse Stock Split info
Market Cap: $35.347M info
Sentiment: Negative
View Wiseek Article
ENLV
Jan 23, 2026, 8:03 AM EST
Filing Type: 6-K
Importance Score:
7
Enlivex to Delist from Tel Aviv Stock Exchange, Focus on Nasdaq Trading
Price at Filing: $1.07
Real-time Price: $2.10 info
Change: Reverse Stock Split info
Market Cap: $35.347M info
Sentiment: Neutral
View Wiseek Article
ENLV
Jan 07, 2026, 8:02 AM EST
Filing Type: 6-K
Importance Score:
7
Enlivex's Primary Digital Treasury Asset, RAIN Token, Listed on KuCoin Exchange
Price at Filing: $0.8174
Real-time Price: $2.10 info
Change: Reverse Stock Split info
Market Cap: $35.347M info
Sentiment: Positive
View Wiseek Article
ENLV
Jan 06, 2026, 4:21 PM EST
Filing Type: 424B3
Importance Score:
9
Enlivex Registers 212M Shares for Resale by Private Placement Investors; Pivots to Digital Asset Treasury Strategy
Price at Filing: $0.8173
Real-time Price: $2.10 info
Change: Reverse Stock Split info
Market Cap: $35.347M info
Sentiment: Negative
View Wiseek Article